SOD1 and uveitis: Technique optimization allowed for more effective SOD1 interactions with polymers in nanoparticles and increased the residual SOD1 activity yield within Nano-SOD1 formulation; (ii) Nano-SOD1 storage stability studies showed that both the hydrodynamic diameter and SOD1 activity of the Nano-SOD1 formulation remained practically unchanged for at least 60 days at 4 °C; (iii) NanoSOD1’s ability to reduce inflammatory processes in the eye was demonstrated in vivo in rabbits with immunogenic uveitis representing the inner vascular eye tract inflammation.